What is the recommended adult dosing of fenofibrate and how should it be adjusted for renal impairment, hepatic disease, elderly patients, and pediatric use?

Fenofibrate Dosing

For primary hypercholesterolemia or mixed dyslipidemia, initiate fenofibrate at 160 mg once daily with meals; for severe hypertriglyceridemia, start at 54-160 mg daily with a maximum of 160 mg daily. 1

Standard Adult Dosing

Primary Hypercholesterolemia or Mixed Dyslipidemia:

• Initial dose: 160 mg once daily with meals 1
• Fenofibrate must be administered with food to optimize bioavailability 1

Severe Hypertriglyceridemia:

• Initial dose: 54-160 mg once daily with meals 1
• Maximum dose: 160 mg once daily 1
• Individualize dosing based on patient response, with lipid reassessment at 4-8 week intervals 1
• Discontinue therapy if inadequate response after 2 months at maximum dose 1

Renal Impairment Dosing

Mild to Moderate Renal Impairment:

• Start at 54 mg once daily 1
• Increase dose only after evaluating renal function and lipid levels at this initial dose 1
• Monitor renal function periodically, as fenofibrate can reversibly increase serum creatinine 1
• Evidence from the FIELD study demonstrates that patients with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) benefit from long-term fenofibrate without excess safety concerns 2

Severe Renal Impairment:

• Fenofibrate is contraindicated in severe renal dysfunction, including dialysis patients 1
• The drug is not dialyzable and has markedly prolonged half-life in renal failure 3

Hepatic Impairment

Active Liver Disease:

• Fenofibrate is contraindicated in active liver disease 1

Mild Hepatic Impairment:

• Recent pharmacokinetic data show fenofibric acid exposure is approximately 25% higher in mild hepatic impairment 4
• Exercise caution and monitor liver function closely (baseline and periodic ALT, AST, total bilirubin) 1
• Discontinue if signs of liver injury develop or elevated enzymes persist 1

Advanced Hepatic Fibrosis:

• Traditionally contraindicated, though recent data suggest fenofibrate 48 mg may be tolerated in advanced fibrosis due to metabolic-associated fatty liver disease, with 60-80% higher exposure in F3-F4 fibrosis 4
• Avoid use unless benefits clearly outweigh risks, and use lowest effective dose with intensive monitoring 4

Geriatric Patients

• Select dose based on renal function 1
• Elderly patients are at increased risk for myopathy and rhabdomyolysis, particularly when fenofibrate is combined with statins 1
• Assess renal function before initiating therapy and follow renal impairment dosing guidelines as appropriate 1

Pediatric Use

• Fenofibrate is not FDA-approved for pediatric use 1
• Safety and efficacy have not been established in children
• The FDA label does not provide pediatric dosing recommendations 1

Critical Monitoring and Safety Considerations

Baseline and Periodic Monitoring:

• Liver function tests (ALT, AST, total bilirubin) at baseline and periodically 1
• Renal function, particularly in patients with baseline impairment 1
• Lipid panel at 4-8 week intervals initially, then periodically 1
• Consider dose reduction if lipid levels fall significantly below target range 1

Important Drug Interactions:

• Statin combination therapy: Increased risk of myopathy/rhabdomyolysis, particularly in elderly, diabetic, or renally impaired patients 1
• Coumarin anticoagulants: Adjust anticoagulant dose to maintain desired INR and prevent bleeding 1
• Cyclosporine and bile acid resins require special consideration 1

Contraindications:

• Severe renal dysfunction (including dialysis) 1
• Active liver disease 1
• Gallbladder disease 1
• Known hypersensitivity to fenofibrate 1
• Nursing mothers 1